NIPH Clinical Trials Search

An observational study on the therapeutic effects of GLP-1 receptor agonists and patients' dietary behavior patterns in clinical practice

Basic Information

Recruitment status	Complete
Health condition(s) or Problem(s) studied	type2 diabetes
Date of first enrollment	01/09/2021
Target sample size	180
Countries of recruitment
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome

Change in HbA1c from baseline to 52 weeks after treatment initiation, stratified by baseline food preference and eating behavior.

Secondary Outcome

Stratified by baseline food preference and eating behavior: Proportion achieving target HbA1c at 52 weeks Proportion achieving HbA1c <7.0% at 52 weeks Change in body weight from baseline to 52 weeks Change in body composition from baseline to 52 weeks Change in handgrip strength from baseline to 52 weeks Change in total energy intake and macronutrient intake (FFQ) from baseline to 52 weeks Change in urinary albumin (or urinary protein in patients with diabetic nephropathy stage 3 or higher) from baseline to 52 weeks

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender
Include criteria	Patients with type 2 diabetes who are judged by their physicians to be eligible for GLP-1 receptor agonists. In addition, patients who understand the purpose of the study and have given written consent.
Exclude criteria	1) Patients who have difficulty in following the instructions of the principal investigator or sub-investigator 2) Patients who are judged by the principal investigator or sub-investigator to be unsuitable for this study